BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1328 related articles for article (PubMed ID: 11208392)

  • 1. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
    Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
    Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Plasminogen activators (t-PA and u-PA) and other fibrinolysis parameters in patients with atherosclerosis obliterans and diabetic macroangiopathy].
    Zalewska-Rydzkowska D; Rość D; Ponikowska I; Michalski A; Graczykowska-Koczorowska A; Rydzkowski M
    Pol Merkur Lekarski; 2001 Nov; 11(65):414-7. PubMed ID: 11852811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrinolysis system in patients with bronchial asthma.
    Banach-Wawrzeńczyk E; Dziedziczko A; Rość D
    Med Sci Monit; 2000; 6(1):103-7. PubMed ID: 11208294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Hemostatic disturbances in chronic myeloid leukemia].
    Rość D; Kremplewska-Nalezyta E; Gadomska G; Bielis L
    Wiad Lek; 2007; 60(3-4):138-42. PubMed ID: 17726865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selected parameters of fibrinolysis system in patients with dermatitis herpetiformis.
    Wankiewicz A; Iwan-Zietek I; Kotschy M; Gwieździński Z
    Med Sci Monit; 2002 Mar; 8(3):CR189-92. PubMed ID: 11887034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma fibrinolytic activators and their inhibitors in women suffering from early recurrent abortion of unknown etiology.
    Gris JC; Neveu S; Mares P; Biron C; Hedon B; Schved JF
    J Lab Clin Med; 1993 Nov; 122(5):606-15. PubMed ID: 8228580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.
    Siegbahn A; Ruusuvaara L
    Thromb Haemost; 1988 Dec; 60(3):361-4. PubMed ID: 3149043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Haemostatic disturbances in essential thrombocythosis].
    Rośc D; Gadomska G; Kremplewska-Nalezyta E; Bielis L
    Przegl Lek; 2007; 64(3):121-3. PubMed ID: 17941461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Tissue type plasminogen activator and its inhibition in blood of patients operated on for prostatic carcinoma].
    Iwan-Zietek I; Zietek Z; Kotschy M; Rość D; Tyloch F
    Pol Tyg Lek; 1996 Feb; 51(6-9):91-3. PubMed ID: 8756741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Activation of fibrynolysis in children with chronic B or C hepatitis].
    Michalska K; Szaflarska-Popławska A; Dymek G; Kotschy M
    Pol Merkur Lekarski; 2004 Oct; 17(100):316-20. PubMed ID: 15690691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
    Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H
    J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
    Munkvad S
    Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Laboratory evidence of hyperfibrinolysis in association with low plasminogen activator inhibitor type 1 activity.
    Agren A; Wiman B; Schulman S
    Blood Coagul Fibrinolysis; 2007 Oct; 18(7):657-60. PubMed ID: 17890953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Depression of tissue-type plasminogen activator and enhancement of urokinase-type plasminogen activator as an expression of local inflammation.
    Brommer EJ; Dooijewaard G; Dijkmans BA; Breedveld FC
    Thromb Haemost; 1992 Aug; 68(2):180-4. PubMed ID: 1412164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Plasminogen tissue activator and plasminogen tissue inhibitor in type II diabetes].
    Rość D; Drewniak W; Kotschy M; Graczykowska-Koczorowska A; Raukuć D
    Pol Merkur Lekarski; 1997 Jan; 2(7):24-5. PubMed ID: 9296893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Fibrinolytic system in bronchial asthma after prednisone treatment].
    Banach-Wawrzeńczyk E; Dziedziczko A; Rość D
    Pol Merkur Lekarski; 2000 Jan; 7(43):9-11. PubMed ID: 10765644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibrinolytic activity in peripheral atherosclerosis in the elderly.
    van der Bom JG; Bots ML; Haverkate F; Meyer P; Hofman A; Grobbee DE; Kluft C
    Thromb Haemost; 1999 Feb; 81(2):275-80. PubMed ID: 10064006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasminogen activators t-PA, u-PA and its inhibitor (PAI) in normal males and females.
    Koh SC; Yuen R; Viegas OA; Chua SE; Ng BL; Sen DK; Ratnam SS
    Thromb Haemost; 1991 Nov; 66(5):581-5. PubMed ID: 1803623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hypofibrinolysis after venous occlusion in patients treated with long-term hemodialysis].
    Opatrný K; Vít L; Opatrná S; Sulková S; Bodláková B
    Cas Lek Cesk; 1994 May; 133(11):346-9. PubMed ID: 8004664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concentrations of plasminogen activators and their inhibitors in blood preconceptionally, during and after pregnancy.
    Coolman M; de Groot CJ; Steegers EA; Geurts-Moespot A; Thomas CM; Steegers-Theunissen RP; Sweep FC
    Eur J Obstet Gynecol Reprod Biol; 2006; 128(1-2):22-8. PubMed ID: 16584829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 67.